Phase 3 – Page 5 – Communicable Diseases Research

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

COVID-19 외래 환자의 REGEN-COV 항체 조합 및 결과

Clinical Trial

Published on 2021-12-022022-09-11
Journal: The New England Journal of Medicine [Category] 변종, 임상, 진단, 치료제,

Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients’

중증 COVID-19 환자에서 IL6R의 다형성과 상대적 IL6 상승의 잠재적 상관 관계 평가

Clinical Trial

Published on 2021-12-012022-09-11
Journal: Cytokine [Category] 바이오마커, 변종, 임상,

[키워드] Affect affecting Analysis Assessing association baseline Baseline assessment baseline level blood sample Blood samples clinical response Clinical studies clinical study clinical variable collected Combination Control correlation COVID-19 COVID-19 patient COVID-19 patients COVID19 COVID19 patients cytokine level cytokine levels Cytokine storm defined determine elevated Elevation Genetic Genetic variant genetic variants Glucose help highest hospitalized COVID-19 patient hospitalized COVID-19 patients hospitalized patient hospitalized patients identify IL-6 IL-6 inhibition IL-6 level IL-6 levels IL6 IL6R interleukin-6 Interpretation mild COVID-19 patient Mortality norm not seen outcome oxygen P-value p-value < 0.01 Participants pathophysiology patient population patients Phase 3 Placebo plasma Plasma levels Pneumonia polymorphism randomized study receiving Regulatory report robust rs2228145 Sequencing analysis serum severe and mild COVID-19 patients severe COVID-19 severe patients severity shown significantly significantly increased supplemental oxygen support tested the patient tradipitant Treatment unlikely variant variants were measured while WHO whole genome Whole genome sequencing
[DOI] 10.1016/j.cyto.2021.155662 PMC 바로가기 [Article Type] Clinical Trial

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

입원한 성인 COVID-19(COV-BARRIER) 치료를 위한 바리시티닙의 효능 및 안전성: 무작위, 이중 맹검, 병행군, 위약 대조 3상 시험

Clinical Trial

Published on 2021-12-012022-09-11
Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 치료법, 치료제,

[키워드] 1:1 95% CI Abstract addition all-cause mortality anti-inflammatory properties antivirals Asia assigned available data Baricitinib baseline Care Combination company Corticosteroids country death defined Dexamethasone Disease progression dose double-blind Efficacy and safety enrolled Europe evaluate event exploratory Follow-up French frequencies Frequency hazard ratio High-flow oxygen hospitalised inhibitor intention-to-treat population Invasive mechanical ventilation Janus kinase Japanese Lilly material Mortality non-invasive ventilation North America Odds ratio oxygen parallel-group participant Participants Phase 3 phase 3 trial Placebo placebo group placebo-controlled placebo-controlled trial prevented primary endpoint progressed proportion randomised Randomly receive receiving reduced reduction in Registered Remdesivir risk risk difference safety analyses safety analysis safety population safety profile secondary endpoint selective Serious Adverse Event Serious Adverse Events serious infection serious infections South America Spanish Standard Standard of care study drug systemic corticosteroid systemic corticosteroids the placebo group the primary endpoint thromboembolic translation Treatment two groups venous thromboembolic were assessed with COVID-19
[DOI] 10.1016/S2213-2600(21)00331-3 PMC 바로가기 [Article Type] Clinical Trial

Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning

Original Paper

Published on 2021-11-292022-10-30
Journal: Journal of Medical Internet Research [Category] COVID-19, MERS, SARS,

[키워드] addition Administered Adverse adverse event adverse events AEs age analyzed applied average caused chills chose clinical trial co-occurrence collected comparable concerning conducted content corpus COVID-19 COVID-19 vaccines database dataset deep deep learning diarrhea doses drugs elderly Euclidean distance fatigue Fever first dose frequencies Gam-COVID-Vac Gender headache information Insomnia Lancet learning lymph node enlargement media men Messenger RNA Mild nausea/vomiting objective Pain Pearson correlation performed Phase 3 pruritus reported representation Result resulting Russian language safety profile SARS-CoV-2 second dose sequence significantly more social media Sputnik V Symptom systemic AE Telegram transformer Trial unique vaccination Vaccine vaccine safety Vaccines vector
[DOI] 10.2196/30529 PMC 바로가기 [Article Type] Original Paper

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

Covid-19 백신의 임상 효능 비교 : 체계적인 검토 및 네트워크 메타 분석

Meta-Analysis

Published on 2021-11-232022-08-31
Journal: Scientific Reports [Category] MERS, meta-analysis, SARS, 임상,

[키워드] Above acute respiratory syndrome Ad26.COV2.S assessment assessment tool Bia BNT162b2 Clinical efficacy clinical trial comparison controlled trials CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine database Efficacy eight Epidemiology evaluated Factor followed by Gam-COVID-Vac greater highest Intervention leading logistics mRNA mRNA-1273 mRNA-1273 vaccine mRNA-1273 vaccines Network meta-analysis New nine NMA no statistically significant difference pandemic participant Patient performed Phase 3 Prevent Primary outcome Primary outcomes Probability Randomized controlled trial RCT RCTs registration number respiratory risk risk of bia SARS-CoV-2 searched severe COVID-19 severe disease Side effects significantly statistically statistically significant difference symptomatic symptomatic COVID-19 symptomatic disease systematic review the vaccine the vaccines unique Vaccine Vaccines viral infection was tested while
[DOI] 10.1038/s41598-021-02321-z PMC 바로가기 [Article Type] Meta-Analysis

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine

SARS-COV-2 불활성 백신에 의해 유도 된 항체 및 T 세포에 의한 관심의 변이체 인식

Clinical Trial

Published on 2021-11-092022-08-13
Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition Alpha antibodies antibody approved B.1.1.7 B.1.351 Beta Beta variant binding cellular response Cellular responses Chilean circulating variant clinical trial concern CoronaVac coronavirus D614G death rate Delta delta variant described detect dose elicited ELISPOT enrolled evaluate evaluated Gamma genetic difference genetic differences geometric mean Geometric means house human ACE2 receptor immune response immunization immunization schedule immunization schedules immunized immunogenic in-house ELISA inactivated induced Infection interferon interferon-γ-secreting T cell interferon-γ-secreting T cells Lineage microneutralization neutralization neutralize Neutralizing antibodies neutralizing antibody neutralizing capacity P.1 pandemic PBMC PBMCs Phase 3 phase 3 clinical trial promote Protective RBD Receptor binding domain Recognition reduced respiratory responsible Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants secreted secretion Seropositivity severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown significant differences spike stimulate subject T cell immunity T cells tested the RBD the SARS-CoV-2 the vaccine titers Vaccine variant variants variants of concern virus Volunteer volunteers were used Wuhan Wuhan, China
[DOI] 10.3389/fimmu.2021.747830 PMC 바로가기 [Article Type] Clinical Trial

Development of an Inactivated Vaccine against SARS CoV-2

SARS COV-2에 대한 불활성 백신의 개발

Article

Published on 2021-11-022022-09-10
Journal: Vaccines [Category] 비임상,

[키워드] Adenovirus Aluminium aluminium hydroxide animal models approved AstraZeneca BALB/c mice breath candidate candidate vaccine changed clinical development clinical trial Complete COVID-19 COVID-19 pandemic COVID-19 vaccine develop development Device distribution Efficacy elicited Emergency use ERUCoV-VAC ferrets hACE2 HCoV help human clinical trial human clinical trials hydroxide immunogenic immunogenicity inactivated Inactivated vaccine include Johnson & Johnson K18-hACE2 Medical devices Medicine mice Moderna mRNA name outbreak Pfizer-BioNTech Phase 3 phase 3 clinical trial progression Protective respiratory safety evaluation SARS CoV-2 SARS-CoV-2 SARS-CoV-2 vaccine Sinopharm Sinovac Spread strain strong immune response the vaccine the WHO transgenic mice TURKOVAC university upper respiratory tract upper respiratory tracts Vaccine vaccine candidate Vaccines Viral viral clearance rate Viral vector viral vectors was used
[DOI] 10.3390/vaccines9111266 PMC 바로가기 [Article Type] Article

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults

Multicenter Study

Published on 2021-11-022023-05-31
Journal: Human vaccines & immunotherapeutics [Category] 두창, 수두, 홍역,

[키워드] Adults Chickenpox immunogenicity Phase 3 Russia Safety Varicella vaccine VARIVAX™
[DOI] 10.1080/21645515.2021.1957414 PMC 바로가기 [Article Type] Multicenter Study

Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents

Multicenter Study

Published on 2021-11-022023-05-31
Journal: Human vaccines & immunotherapeutics [Category] 두창, 수두, 홍역,

[키워드] adolescents Chickenpox children immunogenicity pediatric Phase 3 Russia Safety Varicella vaccine VARIVAX™
[DOI] 10.1080/21645515.2021.1975451 PMC 바로가기 [Article Type] Multicenter Study

Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?

밤라니비맙이 필요한가요? 에테세비맙이 코로나19 치료의 핵심인가?

Article

Published on 2021-11-012022-09-11
Journal: Expert opinion on biological therapy [Category] MERS, SARS, 변종, 진단,